表紙
市場調查報告書

絲胺酸/蘇氨酸蛋白激酶Pim 1:開發中產品分析

Serine/Threonine Protein Kinase Pim 1 - Pipeline Review, H2 2020

出版商 Global Markets Direct 商品編碼 367844
出版日期 內容資訊 英文 54 Pages
訂單完成後即時交付
價格
絲胺酸/蘇氨酸蛋白激酶Pim 1:開發中產品分析 Serine/Threonine Protein Kinase Pim 1 - Pipeline Review, H2 2020
出版日期: 2020年07月31日內容資訊: 英文 54 Pages
簡介

本報告提供以絲胺酸/蘇氨酸蛋白激酶Pim 1為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

絲胺酸/蘇氨酸蛋白激酶Pim 1 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Incyte Corp
  • Inflection Biosciences Ltd
  • Jasco Pharmaceuticals LLC
  • Novartis AG
  • Tolero Pharmaceuticals Inc

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2521TDB

Summary:

According to the recently published report 'SerineThreonine Protein Kinase Pim 1 - Pipeline Review, H2 2020'; Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) pipeline Target constitutes close to 15 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.

Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Proto-oncogene serine/threonine-protein kinase Pim-1 is an enzyme encoded by the PIM1 gene. It promotes cell cycle progression and tumorigenesis by down-regulating expression of a regulator of cell cycle progression CDKN1B at both transcriptional and post-translational levels. It mediates survival signaling through phosphorylation of BAD which induces release of the anti-apoptotic protein Bcl-X (L)/BCL2L1. It phosphorylation of MAP3K5, another proapoptotic protein by PIM1 significantly decreases MAP3K5 kinase activity and inhibits MAP3K5-mediated phosphorylation of JNK and JNK/p38MAPK subsequently reducing caspase-3 activation and cell apoptosis.

The report 'SerineThreonine Protein Kinase Pim 1 - Pipeline Review, H2 2020' outlays comprehensive information on the Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 7 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Immunology and Respiratory which include indications Hematological Tumor, Prostate Cancer, Myelofibrosis, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Asthma, Bladder Cancer, Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-Cell Lymphoma, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Myeloproliferative Disorders, Myocardial Infarction, Non-Small Cell Lung Carcinoma, Peanut Allergy, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary Myelofibrosis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Secondary Myelofibrosis and Triple-Negative Breast Cancer (TNBC).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1)
  • The report reviews Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Overview
  • Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
  • Amgen Inc
  • CardioCreate Inc
  • Incyte Corp
  • Inflection Biosciences Ltd
  • NewBay Medical Technology Co Ltd
  • Novartis AG
  • Sanofi
  • SARomics Biostructures AB
  • Tolero Pharmaceuticals Inc
  • Vortex Biotechnology Corp
  • Yakult Honsha Co Ltd
  • Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Drug Profiles
  • Drugs to Inhibit PIM1 Kinase for Asthma and Peanut Allergy - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GDC-0570 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Activate PIM1 for Myocardial Infarction - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • IBL-100 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Dormant Products
  • Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Discontinued Products
  • Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Product Development Milestones
  • Featured News & Press Releases
  • May 29, 2020: Tolero Pharmaceuticals presents findings from first clinical studies evaluating investigational agent TP-3654 in patients with advanced solid tumors at ASCO Virtual Annual Meeting 2020
  • Apr 06, 2020: Boston Biomedical announces first patient dosed in phase 1 study of investigational agent TP-3654 in patients with myelofibrosis
  • May 14, 2019: Tolero Pharmaceuticals announces first patient dosed in phase 1 study of investigational agent TP-3654 in patients with advanced solid tumors
  • Oct 23, 2017: Tolero Pharma To Present Preclinical Data Supporting Development of Cancer Drug Candidate TP-3654 for Myc-dependent Triple Negative Breast Cancer
  • Oct 05, 2017: Tolero Pharma to Deliver Keynote Presentations at 9th International Conference on Leukemia and Hematologic Oncology
  • Jun 30, 2014: Tolero's PIM Kinase Inhibitor Demonstrates Promising Activity in Preclinical Models of Urothelial Carcinoma
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

List of Tables

  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Indications, H2 2020
  • Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Number of Products under Investigation by Universities/Institutes, H2 2020
  • Products under Investigation by Universities/Institutes, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Pipeline by Amgen Inc, H2 2020
  • Pipeline by CardioCreate Inc, H2 2020
  • Pipeline by Incyte Corp, H2 2020
  • Pipeline by Inflection Biosciences Ltd, H2 2020
  • Dormant Products, H2 2020
  • Dormant Products, H2 2020 (Contd..1), H2 2020
  • Discontinued Products, H2 2020

List of Figures

List of Figures

  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Top 10 Indications, H2 2020
  • Number of Products by Mechanism of Actions, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Top 10 Molecule Types, H2 2020
  • Number of Products by Stage and Top 10 Molecule Types, H2 2020